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Abstract
Studies assessing the costs of alcoholic liver disease are lacking. We aimed to calculate
the costs of hospitalisations before and after diagnosis compared to population controls
matched by age, sex and socio-economic deprivation. We aimed to use population level
data to identify a cohort of individuals hospitalised for the first time with alcoholic liver dis-
ease in Scotland between 1991 and 2011.Incident cases were classified by disease sever-
ity, sex, age group, socio-economic deprivation and year of index admission. 5 matched
controls for every incident case were identified from the Scottish population level primary
care database. Hospital costs were calculated for both cases and controls using length of
stay from morbidity records and hospital-specific daily rates by specialty. Remaining life-
time costs were estimated using parametric survival models and predicted annual costs.
35,208 incident alcoholic liver disease hospitalisations were identified. Mean annual hospi-
tal costs for cases were 2.3 times that of controls pre diagnosis (£804 higher) and 10.2
times (£12,774 higher) post diagnosis. Mean incident admission cost was £6,663. Remain-
ing lifetime cost for a male, 50–59 years old, living in the most deprived area diagnosed
with acoholic liver disease was estimated to be £65,999 higher than the matched controls
(£12,474 for 7.43 years remaining life compared to £1,224 for 21.8 years). In Scotland,
alcoholic liver disease diagnosis is associated with significant increases in admissions to
hospital both before and after diagnosis. Our results provide robust population level esti-
mates of costs of alcoholic liver disease for the purposes of health-care delivery, planning
and future cost-effectiveness analyses.
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Introduction
Alcoholic Liver Disease (ALD) accounts for significantmorbidity, mortality and economic bur-
den worldwide[1]. The UK has one of the highest rates of ALD inWestern Europe[2,3] and
Scotland is associated with substantially higher rates of alcohol consumption (as measured by
alcohol sales) and alcohol-related harms than the rest of the UK[4]. There is much uncertainty
surrounding trends and the level of burden associated with ALD across Europe [5,6] as com-
parisons are hindered by the complex aetiology of liver disease [5], issues with late diagnosis
and under-reporting of alcohol as a contributing factor [5]. Studies looking at the costs associ-
ated with ALD have estimated either population level costs [7,8] or episode based costs [9,10]
and have not distinguished incident cases from readmissions. To our knowledge there are no
studies which examine the costs associated with individual cases of ALD nor any costs studies
using matched controls.
In this study, costs and survival data were modelled to allow annual costs per incident case
and remaining lifetime costs to be estimated. In addition we estimated costs of incident admis-
sion according to disease severity. Use of population level data and the comparison with matched
controls enabled us to produce a robust estimate of the additional hospital costs of an incident
ALD case in Scotland. High quality cost of illness studies are not only valuable for health-care
policymakers and planners, but also provide valuable information for future cost-effectiveness
studies of interventions that aim to prevent incident cases or improve individual prognosis.
This SCottish Alcoholic Liver disease Evaluation (SCALE) study aimed to identify hospital
admissions and associated costs before and after diagnosis and outcomes for all individuals
hospitalised for the first time with ALD in Scotland between 1991–2011 compared to popula-
tion controls matched by age, sex and socio-economicdeprivation.
Materials and Methods
Data sources
Hospital admissions data. Admissions data were drawn from the ScottishMorbidity Rec-
ords (SMR01 and SMR04), which are national data schemes that record comprehensive infor-
mation relating to all inpatient and day cases admitted to acute and psychiatric National
Health Service (NHS) hospitals in Scotland [11]. Several hospital episodesmay be included
within one continuous in-patient stay (CIS).We obtained data for both episodes and CIS as
the episodes detail the hospital and type of care provided and CIS allows consecutive or con-
current episodes to be linked into one continuous admission (stay).
Study population. We obtained anonymised individual level data on all hospital admis-
sions for patients who were admitted with ALD in a principal or secondary diagnostic position
on at least one occasion between 1981 and 2011, including sex, age group and Scottish Index of
Multiple Deprivation (SIMD) quintiles from Information ServicesDivision (ISD), NHS
National Services Scotland (NSS). SIMDmeasures deprivation using a combination of income,
employment, health, education, skills and training, housing, geographic access and crime indi-
cators. ALD admissions were classified using the International Classification of Diseases
(ICD9/ICD-10) codes set used by ISD who are responsible for publishing national statistics on
alcohol-related hospital admissions in Scotland (see Table 1). Definitions of severity groupings
are shown in Table 2
Incident cases. An incident ALD hospitalisation was defined as ALD in any diagnostic
position and no ALD diagnosis was found in hospitalisations for that patient in the preceding
10 years. This length of ‘look back’ period kept the double-counting of cases low (0.7%) while
still retaining over 20 years of study period (1991–2011).
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Controls. The control group was identified from the Community Health Index (a register
of all individuals registered with primary care practices in Scotland) [12,13] and comprised 5
individuals per ALD case. Controls were matched to ALD cases with the same age, sex and
SIMD area deprivation quintile. The only qualifying conditions for controls was that they were
alive at the date of their matched case’s incident hospital admission and had no ALD hospitali-
sations during 1991–2011. The selection of population controls (rather than those in hospital
on the incident date) was motivated by the aim of the study to identify the additional hospital
cost of ALD over and above a typical population cohort.
Death registry data. Date of death, if applicable, was obtained for all cases and controls
who died during the period under review fromNRS.
Cost data. Dates of admission and discharge from the ScottishMorbidity Records were
used to calculate length of stay. This was multiplied by a daily (per diem) cost based on spe-
cialty and hospital codes taken from the Scottish Costs Book 2013 [14]. These costs include
direct costs, indirect costs and allocated overhead and are calculated as set out in the Scottish
Costs BookHealth ServicesManual [15]. In a 2012 assessment dates of admission and dis-
charge and allocated specialty were found to be over 98% accurate [16].
Disease severity. Incident ALD hospitalisations were classified into 3 severity groups as
set out in Table 1 following a detailed clinical review of hospital records. We analysed the sensi-
tivity and specificity of including patients presenting with potential decompensation codes
(not specific to liver disease: coma, jaundice and hematemesis) in group 1. This allowed an inci-
dent ALD hospitalisation to be identifiedwith ALD coded at a secondary diagnostic position.
Methods
Descriptive analysis. We categorised incident admissions by sex, age group, socio-eco-
nomic deprivation category and co-morbidities for each severity grouping. For analysis of
Table 1. Definition of incident ALD hospitalisation disease severity groups (Group: 1) ALD with decompensation (more severe ALD), 2) ALD with-
out decompensation (less severe ALD) and 3) hospitalisation with ALD (but not for ALD)(see Table 2 for definitions of severity groupings).
Group 1 Group 1 Group 2 Group 3
ALD in principal diagnostic position x x
ALD in secondary diagnostic position x x
Decompensation in principal diagnostic position x
Decompensation in secondary diagnostic position x
doi:10.1371/journal.pone.0162980.t001
Table 2. Definitions of severity groupings.
ALD diagnosis codes ICD 10th Revision ALD codes (9th revision in brackets)—K70.0 (571.0) Alcoholic
Fatty Liver, K70.1 (571.1) Alcoholic hepatitis,
K70.2 Alcoholic fibrosis and sclerosis of the liver, K70.3 (571.2) Alcoholic cirrhosis
of the liver, K70.4 Alcoholic hepatic failure,
K70.9 (571.3) Alcoholic liver disease (unspecified)
Decompensation
codes
ICD 10th Revision decomposition codes (9th revision equivalent in brackets)—
C22.0 (I55.0) Primary Liver Cancer, I85.0 (456.0)
Oesophageal Varices (with bleeding), K72.0 (570) Acute and sub-acute failure of
the liver, K72.1(572.2) Chronic hepatic
failure,K72.9 (572.8) Hepatic coma, K76.7 (572.4) Hepatorenal Syndrome, R18
(789.5) Ascites, R17(782.4) Jaundice (>90%
sensitivity on review of patient records), R402 (780.01) Coma (>75% sensitivity on
review of patient records), K766 (5723)
Portal Hypertension.
doi:10.1371/journal.pone.0162980.t002
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hospital admissions the incident admission date for a case was used to attach a pseudo-date of
first ALD event for each of the 5 matched controls. In each 180 day interval for a maximum of
14 years before and after the incident date the percentage of cases and controls hospitalised at
least once in that period and the mean cost per person hospitalised were calculated.
Statistical analysis. Incident hospitalisation rates for 1991–2011 by sex, age group, year of
admission and socio-economicdeprivation were modelled using negative binomial regression.
Mortality during the incident ALD hospitalisation (which we have termed in-hospital mortal-
ity) was modelled using logistic regression to determine adjusted effects on mortality of the
same covariates as used for incident rates as well as the patient’s co-morbidities. For patients
discharged alive, time to all-cause death after incident hospitalisation was modelled using Cox
regression again with the same set of covariates including co-morbidities and with year of dis-
charge replacing year of admission. The number of readmissions per year was calculated,
accounting for different exposure lengths caused by death and the end of follow-up period, and
these rates were modelled using negative binomial regression with the same set of covariates as
for modelling in-hospital mortality. Costs were analysed using generalised linear models
(GLMs) with gamma distribution and a log link with the covariates time period, sex, age group,
socio-economicdeprivation category and year of admission. Despite matching on sex, age
group and socio-economicdeprivation category we adjusted for these variables in our analysis
as ignoring themmay have introduced bias [17].
We estimated remaining lifetime by extrapolating beyond the observed follow-up period
using parametric survivalmodels.We explored different distributions (exponential,Weibull,
etc.) and assessed goodness of fit by comparing observed cumulative incidence curves/survival
probabilities to different model predictions. Although extrapolation is the subject of continuing
debate our period of extrapolation was relatively short and the methodology is now well estab-
lished [18].
Results
Epidemiology
We identified 35,208 incident ALD admissions in the period between 1991 and 2011. Overall
incident ALD hospitalisation rates are shown in S1 Appendix. Characteristics of cases by sever-
ity grouping are shown in Table 3. Definitions of severity groupings are shown in Table 2.
Overall, 6,137 patients died during their incident ALD hospitalisation (out of 35,208 inci-
dent admissions, 17.4%), comprising 4,113 men (out of 19,895, 17.1%) and 2,024 women (out
of 9,176, 18.1%. The results of modelling in-hospital mortality are given in S2 Appendix. The
odds of dying in-hospital were higher for the ‘ALD with decompensation’ group (Odds Ratio
(OR): 1.75, (95% confidence interval (95% CI) 1.63,1.88, p<0.001) and ‘hospitalisation with
ALD (but not for ALD)’ (OR: 1.21, 95% CI 1.20, 1.22, p<0.001) compared to the groups of
‘ALD without decompensation’. There was some evidence of a reduction in in-hospital mortal-
ity over the study periodwith ORs less than 1 since 2003 (OR 2011 vs. 1991: 0.8, 95% CI 0.63,
1.00, p = 0.05).
The remaining 29,071 (82.6%) patients were discharged alive from their incident ALD hos-
pitalisation. Fig 1 shows survival curves for cases by severity grouping and for controls. For
patients with decompensation 5 year survival rates were 40% (95% CI 38%, 41%) and 10 year
survival 25% (95% CI 23%, 26%). For patients without decompensation 5 year survival rates
were 49% (95% CI 48%, 50%) and 10 year survival 32% (95% CI 31%, 33%). S3 Appendix.
shows survival curves by gender by severity group.
The results of modelling all-cause mortality after discharge are shown in S4 Appendix.
There was no evidence that the risk of dying after discharge from incident ALD hospitalisation
Hospital Costs of Alcoholic Liver Disease in Scotland 1991-2011
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had changed between 1991 and 2011. As for inpatient survival, patients with decompensation
at incident admission had a worse outcome if discharged alive with mortality over the full
observation period 30% higher in this group (HR: 1.3, 95% CI 1.25, 1.35, p<0.001) compared
to patients initially admitted without decompensation. The mean (median) number of read-
missions per year (up to death or end of the observation period) for the incident ALD patients
who were discharged alive was 3.1 (1.3). The results of modelling readmission rates are shown
in S5 Appendix. There was strong evidence that the number of readmissions for patients dis-
charged from an incident ALD hospitalisation in more recent years was greater than for those
discharged from incident ALD hospitalisations at the start of the study period (Incidence Rate
Ratio (IRR) (2011 vs. 1991) = 1.61, 95% CI 1.43, 1.81 p<0.001).
Costs
Descriptive analysis. The following figures are not adjusted as in the statistical analysis.
They are for illustration only.
Table 3. Characteristics by incident ALD hospitalisation severity grouping.
Group 1 Group 2 Group 3 All
Description with decompensation without
decompensation
with ALD not for ALD
Number (n) (% of total) 7,330 (20.8%) 12,364 (35.1%) 15,514 (44.1%) 35,208 (100%)
% of n % of n % of n % of n
Sex:
Men 5,000 68.2 8,082 65.4 10,926 70.3 24,008 68.2
Women 2,330 31.8 4,282 34.6 4,588 29.6 11,200 31.8
Age group (years):
< 40 675 9.2 1,734 14 1,709 11.0 4,118 11.7
40–49 1,757 24.0 3,174 25.7 3,316 21.4 8,247 23.4
50–59 2,417 33.0 3,632 29.4 4,366 28.1 10,415 29.6
60–69 1,775 24.2 2,745 22.2 3,945 25.4 8,465 24
70+ 706 9.6 1,079 8.7 2,178 14.0 3,963 11.3
SIMD fifths:
1 (most deprived) 2,823 38.5 5,154 41.7 6,535 42.2 14,512 41.2
2 1,662 22.7 2,902 23.5 3,558 22.9 8,122 23.1
3 1,200 16.4 1,999 16.2 2,450 15.8 5,649 16
4 853 11.6 1,311 10.6 1,607 10.4 3,771 10.7
5 (least deprived) 712 9.7 899 7.3 1,169 7.5 2,780 7.9
Missing 80 1.1 99 0.8 195 1.3 374 1.1
Co-morbidity (10 most frequent):
Alcohol Related 1,616 22.1 2,734 22.1 5,955 38.4 10,305 29.3
Essential Hypertension 638 8.7 963 7.8 1,868 12.0 3,469 9.9
COPD 460 6.3 880 7.1 1,852 11.9 3,192 9.1
Coronary Heart Disease 360 4.9 657 5.3 1,485 9.6 2,502 7.1
Renal Failure 407 5.6 585 4.7 1,173 7.6 2,165 6.2
Diabetes 313 4.3 488 4 967 6.2 1,768 5
Cancer 344 4.7 277 2.2 911 5.9 1,532 4.4
Cerebrovascular Disease 168 2.3 290 2.4 887 5.7 1,345 3.8
Atrial Fibrillation 203 2.8 313 2.5 815 5.3 1,331 3.8
Chronic Heart Failure 155 2.1 263 2.1 823 5.3 1,241 3.5
doi:10.1371/journal.pone.0162980.t003
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Fig 2 shows the percentage of cases and controls who had at least one hospitalisation in a
given 180 day period before and after the incident ALD hospitalisation. Approximately 29% of
the cases were hospitalised in the 180 days before the event and approximately 25% of the cases
were hospitalised between 181–360 days before the event. A large proportion of these were
alcohol-related (AR) hospitalisations– 21% of the incident ALD cohort had an AR hospitalisa-
tion in the year prior to their index admission. As these figures exclude the incident admission
itself, the 47% of cases in hospital in the 180 days following the incident admission were read-
missions. Fig 3 shows that for those hospitalised, costs for cases were 5% higher in the pre-inci-
dent period and 39% higher in the post incident period. Again this figure excludes the incident
admission which, if included, would increase the differential between cases and controls. Fig 4
shows the average cost per person in each 180 day period excluding the incident admission
cost.
Statistical analysis. Table 4 summarises predictedmean and median costs for cases and
controls in the pre-incident period, for the incident admission and in the post-incident period.
Annual costs are used for the pre and post periods as cases and controls had different periods
of exposure during that time. Pre-incident costs were broadly similar for men and women and
mean annual costs for cases were 2.4 times those for controls. Mean incident costs were £6,663
(95% CI £6,511, £6,661) with costs for women 13% higher than those for men. In the post-inci-
dent periodmean annual costs for cases were 10 times those for controls with costs for men
11.9% higher than those for women. Examples of remaining lifetime costs for costs and con-
trols are also summarised in Table 5. Despite shorter life expectancy patients admitted with
Fig 1. Survival curve by severity group shown with 95% confidence intervals. Solid line—ALD with
decompensation, long dash dot—With ALD but not for ALD, short dash—ALD without decompensation and long
dash—controls.
doi:10.1371/journal.pone.0162980.g001
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Fig 2. People hospitalised as a percentage of people alive mid-period.
doi:10.1371/journal.pone.0162980.g002
Fig 3. Mean cost (£) per person hospitalised.
doi:10.1371/journal.pone.0162980.g003
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ALD incur substantial additional costs over their remaining lifetimes when compared to con-
trols. For a man under 40 years old from the least deprived socio-economic category diagnosed
with ALD compared to a matched control additional lifetime hospital costs were estimated to
be £47,220 (with a difference in life expectancy of 30 years). For a woman over 70 years old
from the most deprived socio-economicdeprivation category the additional costs were esti-
mated to be £124,716 (with a difference in life expectancy of 7 years). Confidence intervals
around all costs estimates are narrow due to the large number of observations in this study.
The results of modelling daily pre-incident and post-incident hospital costs per person are
shown in Appendices 6 and 7 (SM1). These costs are calculated by adding the costs of all the
Fig 4. Mean cost (£) per person (whether hospitalised or not).
doi:10.1371/journal.pone.0162980.g004
Table 4. Summary of costs for cases and controls (based on predicted costs from modelling output).
Cases Controls Difference
Mean Median 95% CI Mean Median 95% CI Mean Median
£ £ Lower(£) Higher(£) £ £ Lower(£) Higher(£) £ £
Pre-incident period 1,371 1,269 1,370 1,372 567 522 567 567 804 747
(costs per annum)
Men 1,365 1,258 1,364 1,366 565 519 565 565 800 739
Women 1,385 1,276 1,384 1,386 572 524 572 572 813 752
Incident admission 6,663 6,511 6,661 6,665 N/A N/A N/A N/A N/A N/A
(costs per CIS of initial ALD diagnosis)
Men 6,396 6,259 6,393 6,399 N/A N/A N/A N/A N/A N/A
Women 7,242 7,076 7,238 7,246 N/A N/A N/A N/A N/A N/A
Post-incident period 14,196 10,271 14,182 14,210 1,422 1,036 1,421 1,423 12,774 9,235
(costs per annum)
Men 14,689 10,843 14,671 14,707 1,472 1,092 1,406 1,538 13,217 9,751
Women 13,127 9,289 13,103 13,151 935 1,313 869 1,001 12,192 7,976
doi:10.1371/journal.pone.0162980.t004
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admissions in the observation period (excluding incident costs) and dividing by the number of
days of observation. In the pre-incident period the mean daily cost for cases was 2.4 times that
for controls (IRR 2.44, 95% CI 2.26, 2.62, p<0.001) and 10.2 times in the post-incident period
(IRR 10.15, 95% CI 9.56, 10.78, p<0.001). There was a strong socio-economicgradient in both
periods—costs for patients from the most deprived areas were 51% higher in the pre-incident
period (IRR 1.51 95% CI 1.36, 1.67, p<0.001) than those from the least deprived areas and 57%
in the post-incident period (IRR 1.57, 95% CI 1.45, 1.71, p<0.001). Costs showed a strong age
gradient and daily costs for the 70+ age category were 2.8 times those of the under 40s in the
pre-incident period (IRR 2.81, 95% CI 2.51, 3.16, p<0.001) and 8.7 times in the post-incident
period (IRR 8.68, 95% CI 7.91, 9.53, p<0.001).
The results of modelling overall incident admission costs (ie cost of the CIS when ALD was
first diagnosed) are shown in S8 Appendix. The results show a similarly strong age gradient to
pre incident costs but there is no evidence that socio-economicdeprivation category affected
incident costs. Costs for women were 15% (IRR 1.15, 95% CI 1.10, 1.21 p<0.001) higher than
for men. Incident costs were 26% (IRR 1.26, 95% CI 1.18, 1.33, p<0.001) higher for those
patients with decompensation compared to those without.
There is strong evidence that both overall incident admission and daily post admission costs
have reduced over the study period. Incident costs show a 43% reduction (IRR 0.57, 95% CI
0.48, 0.67, p<0.001) and post incident costs a 28% reduction (IRR 0.72, 95% CI 0.61, 0.85
p<0.001) between 1991 and 2011. Descriptive analysis suggests that these reductions have
Table 5. Estimate of remaining lifetime costs.
Remaining lifetime
costs
Case Control Difference
Annual
mean
95% CI Remaining Remaining Annual
mean
95% CI Remaining Remaining Remaining
cost(£) Lower
(£)
Higher
(£)
life(years) life cost(£) cost(£) Lower
(£)
Higher
(£)
life(years) life cost(£) life cost(£)
Most deprived—
men <40
5,401 5,394 5,408 17.3 93,599 529 529 529 38.3 20,261 73,339
Least deprived—
men <40
3,515 3,501 3,529 18.2 63,832 349 348 350 47.6 16,612 47,220
Most deprived—
men 50–59
12,474 12,464 12,484 7.4 92,682 1,224 1,224 1,224 21.8 26,683 65,999
Least deprived—
men 50–59
7,812 7,797 7,827 8.2 63,902 770 769 771 28.0 21,560 42,342
Most deprived—
men 70+
46,939 46,866 47,012 3.5 165,695 4,608 4,605 4,611 9.3 42,854 122,840
Least deprived—
men 70+
29,109 29,030 29,188 4.1 119,056 2,863 2,859 2,867 12.2 34,929 84,127
Most deprived—
women <40
4,993 4,984 5,002 18.6 92,770 493 493 493 43.2 21,298 71,472
Least deprived—
women <40
3,216 3,196 3,236 19.7 63,323 316 315 317 49.7 15,705 47,618
Most deprived—
women 50–59
11,781 11,766 11,796 8.2 96,840 1,154 1,153 1,155 25.3 29,196 67,644
Least deprived—
women 50–59
7,528 7,508 7,548 9.2 68,881 734 733 735 30.5 22,387 46,494
Most deprived—
women 70+
42,817 42,707 42,927 4.0 171,268 4,232 4,227 4,237 11.0 46,552 124,716
Least deprived—
women 70+
27,742 27,634 27,850 4.6 128,168 2,741 2,736 2,746 13.4 36,729 91,439
doi:10.1371/journal.pone.0162980.t005
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mainly been driven by a reduction in length of stay which has reduced from a median of 10 to
5 days for incident admissions. The mean length of stay for all admissions has reduced from
9.4 days to 4.6 days for cases and from 6.2 days to 3.8 days for controls (S9 Appendix).
Discussion
This study aimed to identify hospital admissions and associated costs before and after diag-
nosis and outcomes for all individuals hospitalised for the first time with ALD in Scotland
between 1991–2011 compared to population controls matched by age, sex and socio-eco-
nomic deprivation.
Main results
Epidemiology. Our results were broadly consistent with previously published statistics
and studies of ALD. Incidence rates identified in the study matched previously published data
for Scotland [19, 20]. The risk of dying in-hospital during an incident ALD hospitalisation for
this cohort was 17.4% overall with higher rates for admissions because of ALD decompensation
(23%). There was evidence that hospital mortality rates had reduced over the study period (OR
0.8, 95% CI 0.63, 1.0, p = 0.05), suggesting a 20% reduction. Survival rates were poor and we
found no evidence of an improvement in survival rates post-discharge over the study period.
Readmission rates post index admission were high and there was evidence that this had
increased substantially over the study period.
Costs. This study found substantial additional costs associated with every incident ALD
admission compared to matched controls. In addition to a mean cost of incident admission of
£6,663, cases were 2.1 times more likely to have been in hospital in the pre-incident period
costing an average of £804 per annum more than matched controls over the 14 years preceding
the incident admission. In the period following the incident admission annual costs associated
with cases were over 10 times those of their matched controls. Even with shorter life expectan-
cies remaining lifetime costs were substantially higher for cases than controls with strong age
and socio-economic gradients. The study found strong evidence that the cost of both incident
and individual post-discharge admissions has reduced over the study period. This reduction
seems to have been drivenmainly by reduced length of stay with median incident length of
stay reducing from 10 to 5 days over the study period and substantial reductions in all lengths
of stay for cases and controls.
Strengths of our approach
This was a population-wide study using data at an individual level which permitted analysis
taking age, sex and socio-economic factors into account. We had the benefit of a large sample
size and detailed follow-up over a long periodwas possible through data linkage of high quality
records. As Scotland benefits from a universal healthcare system free at the point of delivery,
selection bias was minimised. The matched cohort design of the study together with the inclu-
sion of the matched variables in the statistical analyses (age, sex and socio-economicdepriva-
tion category) provided assurance that unmeasured confounding was minimised. The
categorisation of admissions undertaken in this study allowed analysis of outcomes and costs
by disease severity.
Limitations of our approach
A limitation to our study is that incident cases were identified from hospital records only and
that cases of diagnosedALD which did not lead to hospitalisation were not included in our
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analysis. We obtained data on ALD deaths without a hospital admission. There were 5,320
over the full study period (which, had they been admitted to hospital could have increased our
overall incidence by 13.1%). However, these were not included in our analysis as they did not
incur hospital costs. Our analysis did not include emergency hospital attendances where those
did not lead to a hospital admission as these are excluded from the data sources used (SMR01
and SMR04). A further limitation of the study is that only hospital costs were included and not
costs incurred in primary or social care. The majority of care for ALD occurs in hospital [10]
and the inclusion of primary care costs would be likely to increase the additional costs associ-
ated with an incident ALD diagnosis. The inclusion of primary health care data may have
altered our findings in other areas of the study, such as survival, as it is likely that the patients
identified through hospital episodes were the most severe.
A limitation of our study design is that controls were only matched on sex, age and socio-
economic status. We did not match on comorbidity and we did not adjust for it in the cost
analyses as we wished to capture the full difference in costs between cases and controls
although we hypothesised that much of the additional co-morbidity would have resulted from
excess alcohol consumption and therefore should not have been adjusted for. We were unable
to adjust for tobacco consumption despite the likelihood that smoking was more prevalent
among cases.We are therefore unable to attribute the full additional cost of ALD cases to the
ALD diagnosis.
Our method for calculating lifetime costs is based on a modelled daily cost which is then
multiplied by an estimated remaining lifetime. It is possible that high costs for severe cases who
died quickly may have resulted in higher average costs particularly when extrapolated over a
long period (as for the younger age categories). However this possible overestimation might be
partially offset by expected increasing inpatient care as people age and are nearing the end of
life. Future research should examine in more detail the treatment pathways for ALD post diag-
nosis in order to better understand the main drivers of costs.
How our findings fit with the existing literature
Epidemiology. Our findings on incident rates were generally consistent with and have
been superceded by the most recent national data released for Scotland [19,20]. The Monitor-
ing and Evaluating Scotland’s Alcohol Strategy (MESAS) Final Annual report [20] indicated
that incidence rates of ALD decreased further to 48 and 20 per 100,000 per year population for
men and women respectively in the year to April 2013 but have increased for the years to April
2014 and 2015. The in-hospital mortality risk found in this study (17.4%) is not directly com-
parable with other studies for various reasons such as not differentiating between index admis-
sions and other ALD admissions [21], including all liver disease [8] and including only patients
in acute care [22–24]. A US study reflected our finding of in-hospital deaths reducing over
time [10] although their study concerned alcoholic hepatitis. They speculated that the observed
reduction from 10.1% in 2002 to 5.8% by 2010 may have been achieved through better manage-
ment of fluids and infections. A recent Danish study also found decreasing rates of mortality
for alcoholic cirrhosis, although this appears to include both in-hospital and post-discharge
mortality [25]. The lack of socio-economicgradient in in-hospital mortality is contrary to our
findings in other aspects of the study which may suggest that once admitted patients are treated
equally with equal outcome up to discharge.
The high rate of in-hospital mortality for incident ALD hospitalisations reflects a number of
current issues reported in the literature. Difficulties in the early detection of ALDmean that
many patients present late to hospital and their disease is already at an advanced stage [8]. A
review of patients who died of ALD in England in 2013 found that many areas lacked specialist
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care and that less than half of patients had received good care in hospital [26]. Added to these
issues are concerns around lack of options for treatment of ALD [27,28] and lack of research
highlighted in the European Association for the Study of the Liver (EASL) Clinical Practical
Guidelines [5].
Our 5/10 year post-discharge survival rates for patients with ALD decompensation at index
admission (40%/25%) were broadly comparable with mortality rates reported in recent studies
[29–32]. In contrast to the trend in in-hospital mortality the study found no evidence of a
reduction in post-discharge all-causemortality. Factors such as lack of specialist care and lack
of treatment options are also likely to impact on patients post-discharge. For post discharge all-
cause mortality those living in more deprived areas had higher mortality rates than their coun-
terparts in less deprived areas.
This study found substantially higher costs associated with incident ALD cases compared to
matched controls, drivenmainly by the number of days in hospital rather than differences in
daily rates. We are not aware of any other studies that look at costs per incident case of ALD.
Two US studies estimated costs per hospital admission for alcoholic hepatitis [9,10] reported
high and increasing costs driven by increasing daily rates rather than lengths of stay. Many
other studies report population level estimates of annual costs of liver disease and/or alcohol-
related conditions [eg 7,8] and are difficult to compare to our findings in any meaningful way.
Costs for both cases and controls reduced over the study period driven primarily by reduc-
tions in lengths of stay, reflecting national policy in this area ([32], S9 Appendix). The number
of readmissions per year increased over the study periodwith extremely high increases for
readmissions for reasons unconnected to alcohol or liver. This reflects ISD data for Scotland
which found that the increase in hospital stays 2007–2015 was mainly due to repeat visits from
previous patients [33] as well as the findings from two UK based studies [21,34].
Importance for policy, practice and future research. Incident ALD hospitalisation rates
are high by international standards and although they had reduced at the end of our study
period they are now increasing again. Policy makers need to ensure that efforts to reduce popu-
lation level harms related to alcohol are maintained. ALD disproportionately affects those who
live in more deprived areas so effective policies have the potential to reduce health inequalities.
ALD is associated with high in-hospital mortality although this has reduced over time. Fur-
ther research would be useful to determine why in-hospital mortality is so high, what factors
have led to improvements in mortality and the impact of the reducing length of incident stay.
Our study used a novel definition of severity in ALD, which has informed our results. These
groupings may prove useful in future studies.
Post-discharge survival is poor and has not improved over time. The National Confidential
Enquiry into Patient Outcome and Death [26] found a lack of treatment options and subopti-
mal care offered to suffers of liver disease compared to other chronic conditions in England
and the poor prognosis of patients may indicate that the same is true in Scotland. The substan-
tial increase in readmissions merits further investigation as it may be linked to reduced lengths
of stay (possibly with insufficient consideration of psychiatric needs on acute medical wards)
or poor care in the community.
This study established that patients diagnosedwith ALD have had an increased number of
hospital admissions for a long period of time before their diagnosis and many of those admis-
sions were for alcohol-related conditions. This would suggest that there is opportunity for early
assessment of risk of developing ALD and early clinical intervention which should be investi-
gated further. The high cost of hospital care for each incident case of ALD suggests that effec-
tive preventive measures or early treatment options are highly likely to be cost-effective.
Alternative treatment pathways post index admission such as assertive outreach or improved
palliative care [35] should also improve outcomes and/or quality of life.
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The new information on costs provided in this paper can be used in future cost-effectiveness
analyses. However, a more detailed exercise examining treatment pathways for ALD post diag-
nosis and associated costs would be beneficial.
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